STOCK TITAN

[S-8] BioMarin Pharmaceuticals Inc Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

The Form 144 filing shows a Gevo, Inc. (GEVO) shareholder intends to sell up to 28,500 common shares through Stifel Nicolaus on Nasdaq. The block equals roughly 0.01 % of the 239,562,995 shares outstanding and carries an aggregate market value of $35,072, implying a reference price near $1.23 per share. The proposed sale date is 08/05/2025.

The shares were acquired on 08/03/2025 via restricted stock units and will be paid for in cash at settlement. The same seller, Kimberly Bowron, disposed of 35,688 shares during the prior three months for gross proceeds of $45,411. No material adverse information is asserted in the notice, and no additional company financial data are provided.

Il modulo 144 mostra che un azionista di Gevo, Inc. (GEVO) intende vendere fino a 28.500 azioni ordinarie tramite Stifel Nicolaus sul Nasdaq. Il blocco rappresenta circa lo 0,01% delle 239.562.995 azioni in circolazione e ha un valore di mercato complessivo di 35.072 $, con un prezzo di riferimento vicino a 1,23 $ per azione. La data prevista per la vendita è il 05/08/2025.

Le azioni sono state acquisite il 03/08/2025 tramite unità azionarie vincolate e saranno pagate in contanti al momento del regolamento. Lo stesso venditore, Kimberly Bowron, ha ceduto 35.688 azioni nei tre mesi precedenti per un ricavo lordo di 45.411 $. Nel comunicato non sono riportate informazioni negative rilevanti e non sono forniti ulteriori dati finanziari della società.

El formulario 144 muestra que un accionista de Gevo, Inc. (GEVO) planea vender hasta 28,500 acciones comunes a través de Stifel Nicolaus en Nasdaq. El bloque equivale aproximadamente al 0,01 % de las 239,562,995 acciones en circulación y tiene un valor de mercado total de 35,072 $, lo que implica un precio de referencia cercano a 1,23 $ por acción. La fecha propuesta para la venta es el 05/08/2025.

Las acciones fueron adquiridas el 03/08/2025 mediante unidades restringidas de acciones y se pagarán en efectivo al momento del cierre. El mismo vendedor, Kimberly Bowron, vendió 35,688 acciones durante los tres meses anteriores por un ingreso bruto de 45,411 $. No se afirma información adversa material en el aviso y no se proporcionan datos financieros adicionales de la empresa.

Form 144 제출서에 따르면 Gevo, Inc. (GEVO)의 주주가 Stifel Nicolaus를 통해 나스닥에서 28,500 보통주까지 매도할 의향이 있음을 보여줍니다. 이 블록은 총 239,562,995주 발행 주식의 약 0.01%에 해당하며, 총 시장 가치는 35,072달러로 주당 약 1.23달러의 기준 가격을 의미합니다. 제안된 매도 예정일은 2025년 8월 5일입니다.

해당 주식은 2025년 8월 3일 제한 주식 단위로 취득되었으며 결제 시 현금으로 지급될 예정입니다. 동일한 판매자인 Kimberly Bowron은 지난 3개월 동안 35,688주를 처분하여 총 수익 45,411달러를 올렸습니다. 공지에는 중대한 부정적 정보가 없으며 추가 회사 재무 데이터도 제공되지 않았습니다.

Le formulaire 144 indique qu’un actionnaire de Gevo, Inc. (GEVO) a l’intention de vendre jusqu’à 28 500 actions ordinaires via Stifel Nicolaus sur le Nasdaq. Le bloc représente environ 0,01 % des 239 562 995 actions en circulation et a une valeur marchande totale de 35 072 $, ce qui implique un prix de référence proche de 1,23 $ par action. La date de vente proposée est le 05/08/2025.

Les actions ont été acquises le 03/08/2025 via des unités d’actions restreintes et seront payées en espèces lors du règlement. Le même vendeur, Kimberly Bowron, a cédé 35 688 actions au cours des trois derniers mois pour un produit brut de 45 411 $. Aucune information défavorable majeure n’est mentionnée dans l’avis, et aucune donnée financière supplémentaire de la société n’est fournie.

Die Form 144 zeigt, dass ein Aktionär von Gevo, Inc. (GEVO) beabsichtigt, bis zu 28.500 Stammaktien über Stifel Nicolaus an der Nasdaq zu verkaufen. Das Paket entspricht etwa 0,01 % der 239.562.995 ausstehenden Aktien und hat einen Gesamtmarktwert von 35.072 $, was auf einen Referenzpreis von etwa 1,23 $ pro Aktie hinweist. Das geplante Verkaufsdatum ist der 05.08.2025.

Die Aktien wurden am 03.08.2025 über eingeschränkte Aktieneinheiten erworben und werden bei Abwicklung in bar bezahlt. Derselbe Verkäufer, Kimberly Bowron, hat in den letzten drei Monaten 35.688 Aktien verkauft und dabei Bruttoerlöse von 45.411 $ erzielt. Im Hinweis werden keine wesentlichen negativen Informationen angegeben und es werden keine zusätzlichen Finanzdaten des Unternehmens bereitgestellt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small Form 144 sale (~0.01 % float) appears routine and is unlikely to materially impact GEVO’s valuation.

The filing registers 28,500 shares, valued at just $35k, for potential sale. With over 239 million shares outstanding, the transaction is de-minimis. The seller has gradually reduced her position—totaling 64,188 shares in three months—yet even combined proceeds remain immaterial relative to Gevo’s market cap. Absence of adverse disclosures or unusual payment terms suggests a standard liquidity event rather than a signal about fundamentals. I classify the impact on investors as neutral.

Il modulo 144 mostra che un azionista di Gevo, Inc. (GEVO) intende vendere fino a 28.500 azioni ordinarie tramite Stifel Nicolaus sul Nasdaq. Il blocco rappresenta circa lo 0,01% delle 239.562.995 azioni in circolazione e ha un valore di mercato complessivo di 35.072 $, con un prezzo di riferimento vicino a 1,23 $ per azione. La data prevista per la vendita è il 05/08/2025.

Le azioni sono state acquisite il 03/08/2025 tramite unità azionarie vincolate e saranno pagate in contanti al momento del regolamento. Lo stesso venditore, Kimberly Bowron, ha ceduto 35.688 azioni nei tre mesi precedenti per un ricavo lordo di 45.411 $. Nel comunicato non sono riportate informazioni negative rilevanti e non sono forniti ulteriori dati finanziari della società.

El formulario 144 muestra que un accionista de Gevo, Inc. (GEVO) planea vender hasta 28,500 acciones comunes a través de Stifel Nicolaus en Nasdaq. El bloque equivale aproximadamente al 0,01 % de las 239,562,995 acciones en circulación y tiene un valor de mercado total de 35,072 $, lo que implica un precio de referencia cercano a 1,23 $ por acción. La fecha propuesta para la venta es el 05/08/2025.

Las acciones fueron adquiridas el 03/08/2025 mediante unidades restringidas de acciones y se pagarán en efectivo al momento del cierre. El mismo vendedor, Kimberly Bowron, vendió 35,688 acciones durante los tres meses anteriores por un ingreso bruto de 45,411 $. No se afirma información adversa material en el aviso y no se proporcionan datos financieros adicionales de la empresa.

Form 144 제출서에 따르면 Gevo, Inc. (GEVO)의 주주가 Stifel Nicolaus를 통해 나스닥에서 28,500 보통주까지 매도할 의향이 있음을 보여줍니다. 이 블록은 총 239,562,995주 발행 주식의 약 0.01%에 해당하며, 총 시장 가치는 35,072달러로 주당 약 1.23달러의 기준 가격을 의미합니다. 제안된 매도 예정일은 2025년 8월 5일입니다.

해당 주식은 2025년 8월 3일 제한 주식 단위로 취득되었으며 결제 시 현금으로 지급될 예정입니다. 동일한 판매자인 Kimberly Bowron은 지난 3개월 동안 35,688주를 처분하여 총 수익 45,411달러를 올렸습니다. 공지에는 중대한 부정적 정보가 없으며 추가 회사 재무 데이터도 제공되지 않았습니다.

Le formulaire 144 indique qu’un actionnaire de Gevo, Inc. (GEVO) a l’intention de vendre jusqu’à 28 500 actions ordinaires via Stifel Nicolaus sur le Nasdaq. Le bloc représente environ 0,01 % des 239 562 995 actions en circulation et a une valeur marchande totale de 35 072 $, ce qui implique un prix de référence proche de 1,23 $ par action. La date de vente proposée est le 05/08/2025.

Les actions ont été acquises le 03/08/2025 via des unités d’actions restreintes et seront payées en espèces lors du règlement. Le même vendeur, Kimberly Bowron, a cédé 35 688 actions au cours des trois derniers mois pour un produit brut de 45 411 $. Aucune information défavorable majeure n’est mentionnée dans l’avis, et aucune donnée financière supplémentaire de la société n’est fournie.

Die Form 144 zeigt, dass ein Aktionär von Gevo, Inc. (GEVO) beabsichtigt, bis zu 28.500 Stammaktien über Stifel Nicolaus an der Nasdaq zu verkaufen. Das Paket entspricht etwa 0,01 % der 239.562.995 ausstehenden Aktien und hat einen Gesamtmarktwert von 35.072 $, was auf einen Referenzpreis von etwa 1,23 $ pro Aktie hinweist. Das geplante Verkaufsdatum ist der 05.08.2025.

Die Aktien wurden am 03.08.2025 über eingeschränkte Aktieneinheiten erworben und werden bei Abwicklung in bar bezahlt. Derselbe Verkäufer, Kimberly Bowron, hat in den letzten drei Monaten 35.688 Aktien verkauft und dabei Bruttoerlöse von 45.411 $ erzielt. Im Hinweis werden keine wesentlichen negativen Informationen angegeben und es werden keine zusätzlichen Finanzdaten des Unternehmens bereitgestellt.

As filed with the Securities and Exchange Commission on August 5, 2025

Registration No. 333-   

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

BIOMARIN PHARMACEUTICAL INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   68-0397820

(State or other jurisdiction of

Incorporation or organization)

 

(I.R.S. Employer

Identification No.)

770 Lindaro Street

San Rafael, CA 94901

(Address of principal executive offices) (Zip code)

BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, as Amended April 1, 2025

(Full title of the plan)

G. Eric Davis

Executive Vice President, Chief Legal Officer and Secretary

BioMarin Pharmaceutical Inc.

770 Lindaro Street

San Rafael, California 94901

(415) 506-6700

(Name and address of agent for service) (Telephone number, including area code, of agent for service)

 

 

Copies to:

Chadwick Mills

Siana E. Lowrey

Cooley LLP

3 Embarcadero Center

20th Floor

San Francisco, CA 94111-4004

(415) 693-2000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


EXPLANATORY NOTE

On May 20, 2025, the Registrant’s stockholders approved an amendment to the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, as amended (the “2017 Plan”) to increase the number of shares of Common Stock reserved for issuance under the 2017 Plan by 8,000,000 shares. Accordingly, this Registration Statement is being filed with the Securities and Exchange Commission (the “Commission”) to register an additional 8,000,000 shares of Common Stock for future issuance under the 2017 Plan. These additional shares of Registrant’s Common Stock are securities of the same class as other securities for which an original Registration Statement on Form S-8 was filed with the Commission on June 13, 2017 (File No.  333-218695) and subsequent Registration Statements on Form S-8 were filed with the Commission on October 16, 2019 (File No. 333-234231), February 17, 2022 (File No.  333-262824) and November 2, 2023 (File No.  333-275273) (collectively, the “Prior Registration Statements”). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Prior Registration Statements.


PART II

 

ITEM 8.

EXHIBITS

 

Exhibit

Number

  
4.1    Restated Certificate of Incorporation of BioMarin Pharmaceutical Inc., previously filed with the Commission on June  12, 2017 as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.
4.2    Amended and Restated Bylaws of BioMarin Pharmaceutical Inc., previously filed with the Commission on March  3, 2025 as Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.
5.1*    Opinion of Cooley LLP.
23.1*    Consent of KPMG LLP, independent registered public accounting firm.
23.2*    Consent of Cooley (included in Exhibit 5.1 to this Registration Statement on Form S-8). 
24.1*    Power of Attorney (included on the signature page of this Registration Statement on Form S-8). 
99.1    BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, as amended on April  1, 2025, previously filed with the Commission on August 5, 2025 as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June  30, 2025, which is incorporated herein by reference.
107*    Filing Fee Table.
*    Filed herewith


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Rafael, State of California, on August 5, 2025.

 

BIOMARIN PHARMACEUTICAL INC.
By:  

/s/ Brian R. Mueller

  Brian R. Mueller
  Executive Vice President and Chief Financial
  Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Alexander Hardy and Brian R. Mueller, and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature    Title   Date

/s/ Alexander Hardy

Alexander Hardy

  

President and Chief Executive Officer

(Principal Executive Officer)

  August 5, 2025

/s/ Brian R. Mueller

Brian R. Mueller

  

Executive Vice President and Chief Financial Officer

(Principal Financial Officer)

  August 5, 2025

/s/ Erin Burkhart

Erin Burkhart

  

Group Vice President and Chief Accounting Officer

(Principal Accounting Officer)

  August 5, 2025

/s/ Richard A. Meier

Richard A. Meier

   Chair of the Board of Directors   August 5, 2025

/s/ Elizabeth McKee Anderson

Elizabeth McKee Anderson

   Director   August 5, 2025

/s/ Barbara W. Bodem

Barbara W. Bodem

   Director   August 5, 2025


/s/ Ian T. Clark

Ian T. Clark

   Director   August 5, 2025

/s/ Athena Countouriotis

Athena Countouriotis

   Director   August 5, 2025

/s/ Willard H. Dere

Willard H. Dere

   Director   August 5, 2025

/s/ Mark J. Enyedy

Mark J. Enyedy

   Director   August 5, 2025

/s/ Maykin Ho

Maykin Ho

   Director   August 5, 2025

/s/ Robert J. Hombach

Robert J. Hombach

   Director   August 5, 2025

/s/ Timothy P. Walbert

Timothy P. Walbert

   Director   August 5, 2025

FAQ

How many GEVO shares are covered by the Form 144 notice?

28,500 common shares are proposed for sale.

What percentage of Gevo’s shares outstanding do the 28,500 shares represent?

Approximately 0.01 % of the 239,562,995 shares outstanding.

When is the proposed sale date for the shares?

The filer lists an approximate sale date of 08/05/2025.

What is the aggregate market value of the proposed sale?

The filing cites an aggregate value of $35,072.

Has the seller recently disposed of additional GEVO shares?

Yes. 35,688 shares were sold in the past three months for $45,411 total proceeds.

Which broker is facilitating the transaction?

Stifel Nicolaus & Company Inc., located at 501 N Broadway, St. Louis, MO 63102.

Does the Form 144 disclose any new adverse information about Gevo?

No. The filer states they are unaware of any non-public material adverse information.
Biomarin Pharmaceutical Inc

NASDAQ:BMRN

BMRN Rankings

BMRN Latest News

BMRN Latest SEC Filings

BMRN Stock Data

11.15B
190.29M
0.78%
100.5%
3.19%
Biotechnology
Pharmaceutical Preparations
Link
United States
NOVATO